,0
symbol,SESN
price,1.065
beta,1.04242
volAvg,2147458
mktCap,137747104
lastDiv,0.0
range,0.37-1.54
changes,-0.015
companyName,Sesen Bio Inc
currency,USD
cik,0001485003
isin,US8177631053
cusip,817763105
exchange,NasdaqGS
exchangeShortName,NASDAQ
industry,Biotechnology
website,http://www.elevenbio.com/
description,"Sesen Bio, Inc. engages in designing, engineering, and developing of targeted protein therapeutics. The company is headquartered in Cambridge, Massachusetts and currently employs 17 full-time employees. The firm is focused on developing antibody-drug conjugate (ADC) therapies for the treatment of cancer. Its product pipeline includes Vicinium, Vicinium in combination with checkpoint inhibator, durvalumab, and VB6-845d. The Companyâ€™s lead program, Vicinium, is a fusion protein in Phase III development for the treatment of non-muscle invasive bladder cancer (NMIBC). The company targets epithelial cell adhesion molecule (EpCAM) antigens on the surface of tumor cells to deliver a potent cytotoxin, Pseudomonas Exotoxin A (ETA) directly to cancer cells."
ceo,Mr. Thomas Cannell
sector,Healthcare
country,US
fullTimeEmployees,25
phone,16174448550
address,245 1st St Ste 1800
city,Cambridge
state,MASSACHUSETTS
zip,02142
dcfDiff,
dcf,1.71922
image,https://financialmodelingprep.com/image-stock/SESN.jpg
ipoDate,2014-02-06
defaultImage,True
